secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001437749-24-001197
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics enters strategic agreements with Lantheus; $28M upfront, $33M equity investment possible
--------------------------------------------------------------------------------

- Lantheus pays $28M upfront for exclusive option to license Pb212-VMT-α-NET (neuroendocrine tumors) and co-fund IND studies for PSMA/GRPR candidates.
- Lantheus to invest up to ~$33M for up to 19.9% equity (56.3M shares) at lower of $0.59/share or price in qualified $50M+ financing.
- Perspective to acquire Lantheus' Somerset, NJ radiopharmaceutical manufacturing facility for $8M cash, subject to regulatory approvals.
- Lantheus gets board observer, information rights, standstill, and right of first offer on M&A for 12 months.
- Closings of equity investment and asset purchase conditioned on Perspective raising at least $50M in qualified third-party financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000143774924001197/0001437749-24-001197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000143774924001197/isr20240109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-001197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer